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instrument and the Skindex-29 questionnaire appear to have rea-
sonable performance and validity for ChHD patients. Further
validation studies with a larger sample size will be needed to
conﬁrm these ﬁndings.
PES17
IMPROVED HEALTH-RELATED QUALITY OF LIFE FOLLOWING
SUSTAINED REDUCTIONS IN ANTI DS-DNA ANTIBODYS
[ÁDSDNA AB] IN PATIENTS WITH SYSTEMIC LUPUS
ERYTHEMATOSUS (SLE) AFTER TREATMENT WITH LJP394
Crawford B1, Strand V2
1Mapi Values, Boston, MA, USA; 2Stanford University School of
Medicine, Palo Alto, CA, USA
OBJECTIVE: Treatment with LJP 394 results in decreased
ÁdsDNA Ab in patients with SLE. Sustained reductions were
demonstrated in 2 RCTs of 298 [phase 3] and 189 [phase 2/3]
SLE patients with a history of renal disease, statistically favor-
ing active vs placebo treatment. SF-36 was assessed at baseline,
6 and 12 months in phase 3 to evaluate the impact of sustained
reductions on patient reported HRQOL. METHODS: Sustained
reductions: ≥20% decreases from baseline in ≥2/3 of all ÁdsDNA
Ab determinations deﬁned “responders”. Minimal clinically
important differences [MCID] were based on a 15-point global
change scale. RESULTS: In phase 3, 31.4% patients were respon-
ders, 63 in LJP394, 28 in placebo; a ratio of 2.25 favoring active
treatment. At 6 months, 31.3% were responders: 59 LJP394 and
27 placebo; a ratio of 2.2. At 6 months, responders reported
improvement in all domains of SF-36 with the largest increases
in bodily pain (8.2), vitality (8.0), general health perceptions
(6.6) and physical function (5.7). Non-responders reported wors-
ening in all but 3 domains, which remained unchanged (vitality
(1.3), mental health (0.9), and role emotional (0.0)). At 12
months, 43 LJP394 and 24 placebo treated patients were respon-
ders; a ratio of 1.8; 35.3% overall. Improvements reported by
responders increased by month 12, with largest changes in role
physical (13.8), vitality (10.2), general health proﬁle (9.3), and
bodily pain (7.3), again with no change or deterioration in non-
responders. Improvements in domain scores were reﬂected in
physical component summary [PCS] score. MCID was deter-
mined to range from 6.7 to 11.4 points in domain and 3.4 to
3.9 in PCS scores, consistent with literature reported estimates
of 5–10 and 2.5–5.0 points. CONCLUSION: Sustained reduc-
tions in ÁdsDNA Ab levels lead to improvement in patient
reported HRQOL. These improvements are clinically meaning-
ful, regardless of treatment group. LJP394 administration
resulted in 1.8 to 4.0 times more responders than placebo.
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OBJECTIVE: To describe an evaluation of isotretinoin prescrib-
ing patterns before and after implementation of the System to
Manage Accutane-Related Teratogenicity (SMART), a risk man-
agement plan developed by Hoffmann-LaRoche to minimize the
risk of pregnancy among women taking Accutane. METHODS:
The IMS Health, National Prescription Audit Plus provided
information on the number of prescriptions dispensed for the
pre- (1 April 2001–31 March 2002) and post- (1 April 2002–31
March 2003) SMART periods. Data on patient gender, pre-
scriber speciality, and physician-reported severity of indication
for use were obtained from AdvancePCS, a large pharmacy 
beneﬁts manager (PBM), and the IMS Health, National Disease
and Therapeutic Index. RESULTS: In the 12-months prior 
to SMART, 1,508,000 prescriptions were dispensed for
isotretinoin; declining approximately 23% to 1,160,000 pre-
scriptions in the year following SMART. Dermatologists were 
the most common prescribers of isotretinoin, accounting for
76% and 80% of the prescriptions dispensed in the year 
before and after SMART, respectively. Half of the claims for
isotretinoin were for females in both the pre- and post-SMART
eras. The severity of indication for use did not appear to be
affected by SMART. In the year pre-SMART, 53% of the
isotretinoin mentions during ofﬁce visits for female patients were
for “severe” acne cases, compared to 55% in the year post-
SMART. Similar percentages were seen for males. CONCLU-
SIONS: SMART may have inﬂuenced the number of isotretinoin
prescriptions dispensed, but appeared to have little impact on
other variables such as prescriber speciality and severity of indi-
cation for use.
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OBJECTIVES: To examine the effects of initial ziprasidone dose
on discontinuation rates, using the PharMetrics integrated
medical and pharmacy claims data. METHODS: Patients ≥18
years with a diagnosis of schizophrenia and a ziprasidone claim
between March 2001 and February 2003 continuously enrolled
for ≥6 months before and ≥3 months after initiation of ziprasi-
done were stratiﬁed by initial daily dose (≥40mg and <80mg
[low] vs. ≥80mg and <120mg [medium] vs. 120mg–160mg
[high]). The 6-month risk of discontinuation was examined using
Cox proportional hazards models controlling for gender, psy-
chiatric comorbidities, and pre-ziprasidone utilization of antipsy-
chotics (atypical, conventional, none). RESULTS: Mean age of
the sample (n = 1058) was 38 years; 42% were male. The 
6-month risk of discontinuation was signiﬁcantly greater in
patients with a low vs high initial dose (HR = 1.357, 95% CI =
1.070, 1.721; p = 0.012) and trended towards signiﬁcance when
comparing a medium vs high initial dose (HR = 1.163, 95% 
CI = 0.905, 1.494; p = 0.237). The largest difference in discon-
tinuation rates between dose groups occurred after the ﬁrst 
prescription. CONCLUSIONS: Patients initiating ziprasidone
therapy with an initial dose of at least 120mg/day had better
medication adherence compared with those initiating at lower
doses. This may reﬂect improved efﬁcacy at daily doses ≥120mg.
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